Previous 10 | Next 10 |
Interpace Diagnostics Group (NASDAQ: IDXG ) has reached an agreement with SelectHealth to provide its proprietary thyroid cancer assays, ThyGeNEXT and ThyraMIR to latter’s more than 850,000 members in Utah and Idaho. More news on: Interpace Diagnostics Group, Inc., Healt...
Expected to Benefit More than 850,000 Members PARSIPPANY, NJ, July 22, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it has reached an agreement with SelectHealth (a plan associated with Intermountain Healthcare) to provide its propriet...
Interpace Diagnostics (NASDAQ: IDXG ) has executed an agreement with the Helomics division of Predictive Oncology (NASDAQ: POAI ). More news on: Interpace Diagnostics Group, Inc., Predictive Oncology Inc., Healthcare stocks news, Stocks on the move, Read more ...
PARSIPPANY, NJ, July 18, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or the “Company), announced today that it has executed an agreement with the Helomics division of Predictive Oncology (NASDAQ: POAI), a company focused on app...
Interpace Diagnostics (NASDAQ: IDXG ) has acquired Cancer Genetics' (NASDAQ: CGIX ) Biopharma Services business for ~$23.5M subject to adjustments. The business generated ~$15M in revenue in 2018. More news on: Interpace Diagnostics Group, Inc., Cancer Genetics, Inc., Healthcare stocks n...
Conference Call to be Held Tomorrow, Tuesday July 16, 2019 @ 8:30 am ET PARSIPPANY NJ, July 15, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or the “Company”), announced today that it has acquired assets and certain l...
Interpace Diagnostics ( IDXG +9.7% ) says its ThyGeNEXT and ThyraMIR tests for thyroid cancer are now covered by Independence Blue Cross , which covers nearly 2.5M members in Philadelphia and southern Pennsylvania. More news on: Interpace Diagnostics Group, Inc., Healthcare stocks news,...
PARSIPPANY NJ, June 20, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that its ThyGeNEXT™ and ThyraMIR ® tests for thyroid cancer are now covered by Independence Blue Cross (Independence), providing plan benefits coverage for its memb...
Rome, ITALY, June 13, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG), a fully integrated bioinformatics and commercial molecular diagnostic company, today announced that Dr. Sydney D. Finkelstein, Interpace’s Chief Scientific Officer, will present at the Wo...
Interpace Diagnostics Group, Inc. (IDXG) Q1 2019 Earnings Conference Call May 13, 2019, 04:30 PM ET Company Participants Jack Stover - President & CEO Jim Early - CFO Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Yi Chen - H.C. Wainwright Benjamin Ha...
News, Short Squeeze, Breakout and More Instantly...
Interpace Biosciences Inc. Company Name:
IDXG Stock Symbol:
NASDAQ Market:
Interpace Biosciences Inc. Website:
PARSIPPANY, NJ, June 04, 2024 (GLOBE NEWSWIRE) -- Interpace Diagnostics ® , a subsidiary of Interpace Biosciences ® (OTCQX: IDXG), is proud to announce that new data demonstrating the application of advanced sequencing technologies in pancreatic cancer was published as an e-ab...
PARSIPPANY, NJ, May 09, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2024 and provided a business and financial update. First quarter Net ...
GD Culture Group Limited (GDC) is expected to report for Q4 2023 Citizens Inc. Class A ($1.00 Par) (CIA) is expected to report for quarter end 2023-12-31 Escalade Incorporated (ESCA) is expected to report for Q4 2023 Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31...